Non-alcoholic Fatty Liver Disease in Children

Author:

Muzurović Emir12,Polyzos Stergios A.3,Mikhailidis Dimitri P.45,Borozan Sanja1,Novosel Dušanka26,Cmiljanić Oleg26,Kadić Nataša2,Mantzoros Christos S.7

Affiliation:

1. Department of Internal Medicine, Endocrinology Section, Clinical Centre of Montenegro, Podgorica, Montenegro

2. Faculty of Medicine, University of Montenegro, Ljubljanska bb, 81000, Podgorica, Montenegro

3. First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

4. Department of Clinical Biochemistry, Royal Free Hospital Campus, Medical School, University College London (UCL), Pond Street, London NW3 2QG, UK

5. Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, UAE

6. Institute for Children's Diseases, Gastroenterology Section, Clinical Centre of Montenegro, Podgorica, Montenegro

7. Departments of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA and Boston VA Healthcare System, Harvard Medical School, Boston, MA 02115, USA

Abstract

Abstract: Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in the paediatric age. The growing prevalence of NAFLD and its advanced phenotype, non-alcoholic steatohepatitis (NASH), in children and adolescents parallels similar trends in obesity and type 2 diabetes mellitus. This trend may have serious long-term implications, including hepatic and extra-hepatic morbidity and mortality, the latter being related mostly due to cardiovascular disease and malignancies. This narrative review, which included 236 articles, summarizes current evidence on paediatric NAFLD, including pathophysiology, risk factors, complications, prevention and treatment (existing and emerging). Early recognition of NAFLD followed by timely and adequate management seems to be important on an individual basis. A global “call to action” regarding paediatric NAFLD seems appropriate to mitigate the burden of this disease.

Publisher

Bentham Science Publishers Ltd.

Subject

Cardiology and Cardiovascular Medicine,Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3